IMUX Immunic: Multiplikator Forward P/S
Analyzing the forward P/S trend in GURU.Markets reveals how small molecule patents protect Immunic, Inc. (IMUX) positions against injectable drugs. The convenience of tablets for psoriasis and sclerosis therapy accelerates business expansion, while determines the current status of the parameter. Anticipation of Phase 2 trial results serves as a powerful driver for the company's valuation growth.
Rincian metrik lan analitis perusahaan immunic-therapeutics.com (IMUX)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Immunic, Inc.|IMUX - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Immunic|IMUX - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku IMUX|IMUX - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Immunic|Indikator likuiditas cepet immunic-therapeutics.com
- data bathi bisnis lan rasio investasi:
IMUX - Bathi pungkasan|Proyeksi bathi mangsa ngarep Immunic, Inc.|IMUX - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Immunic|IMUX - Rasio P/E diaturake wutah|Pangali EV/EBITDA IMUX|IMUX - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Immunic|IMUX - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan immunic-therapeutics.com|IMUX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Immunic, Inc.
- data dodolan lan asil:
Pambiji fundamental perusahaan:Immunic Inc IMUX
For Immunic, Inc. (IMUX), the forward P/S reflects market expectations for the future monetization of immunological developments, correlating current capitalization with projected sales volume. The trend of the forward P/S valuation is based on a daily recalculation of consensus revenue forecasts, accounting for the high readiness of contract manufacturing capacities to release drugs, which allows investors to promptly assess the asset's degree of overbought status relative to its potential.
Analisis perusahaan pesaing
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Abivax Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan immunovant.com|Rasio rega marang prakiraan pendapatan Kiniksa|Multiplikator forward rega marang pendapatan Grifols SA (GRFS)|Multiplikator forward rega marang pendapatan ADPT (Adaptive Biotechnologies Corp)|Multiplikator Forward P/S Celldex Corp (CLDX)|Rasio rega marang prakiraan pendapatan Aurinia Pharmaceuticals AUPH|BCRX: Kapitalisasi marang prakiraan pendapatan|Vera Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Dianthus Therapeutics Inc DNTH|PHVS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan AbCellera Corp|Multiplikator forward rega marang pendapatan TRML|PGEN: Rega forward marang dodolan|Multiplikator Forward P/S PHAR|Rasio kapitalisasi marang dodolan sing dikarepake Nektar Therapeutics Inc|Rasio rega marang prakiraan pendapatan Upstream Bio Corp UPB|ZBIO: Kapitalisasi marang prakiraan pendapatan|Immunome, Inc. - Multiplikator Forward P/S|gossamerbio.com (GOSS) - Multiplikator forward rega marang pendapatan|KALV (KalVista Pharmaceuticals, Inc.) - Multiplikator forward rega marang pendapatan|SEPN - Rasio kapitalisasi marang dodolan sing dikarepake|PVLA (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|Savara Pharma (SVRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Rigel Pharmaceuticals (RIGL)|Multiplikator forward rega marang pendapatan anaptysbio.com ANAB|Astria Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S enGene Holdings Inc ENGN|RAPT: Multiplikator forward rega marang pendapatan|JBIO (Aerovate Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|Aclaris Therapeutics (ACRS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Multiplikator Forward P/S|CABA: Rega forward marang dodolan|Multiplikator Forward P/S VTYX|Multiplikator Forward P/S Theratechnologies, Inc (THTX)|Rasio rega marang prakiraan pendapatan Avalo Therapeutics, Inc AVTX|Rega forward marang dodolan ELDN|AGEN - Rasio rega marang prakiraan pendapatan|Climb Bio Inc. (CLYM) - Multiplikator forward rega marang pendapatan|ZURA: Multiplikator Forward P/S|aTyr Pharmaceuticals (ATYR) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ADAG|IMA: Rega forward marang dodolan|Multiplikator Forward P/S STTK|Rasio kapitalisasi marang dodolan sing dikarepake equilliumbio.com|Rasio rega marang prakiraan pendapatan Connect Biopharma Holdings Limited CNTB|ATRA - Multiplikator forward rega marang pendapatan|IFRX - Rasio rega marang prakiraan pendapatan|x4pharma.com (XFOR) - Multiplikator forward rega marang pendapatan|ACET (adicetbio.com) - Multiplikator forward rega marang pendapatan|Celularity (CELU) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan INmune Bio Corp|Kapitalisasi marang prakiraan pendapatan BRNS (Barinthus Biotherapeutics Corp)|Multiplikator Forward P/S KZR|SABS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S AKTX (Akari Therapeutics Plc)|Rasio kapitalisasi marang dodolan sing dikarepake Enlivex Therapeutics Ltd (ENLV)|QTTB - Rasio rega marang prakiraan pendapatan|GeoVax Corp (GOVX) - Multiplikator forward rega marang pendapatan|Edesa Biotech, Inc. (EDSA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ibioinc.com|Multiplikator forward rega marang pendapatan CARM|Multiplikator Forward P/S XTL Biopharmaceuticals Ltd|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S APVO (Aptevo Therapeutics Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake AIM ImmunoTech, Inc. (AIM)|Aditxt Corp - Multiplikator Forward P/S|GRI Bio Inc (GRI) - Multiplikator forward rega marang pendapatan|XRTX (XORTX) - Multiplikator forward rega marang pendapatan|Vyome Therapeutics - Rega forward marang dodolan|REVB (Revelation Biosciences) - Multiplikator Forward P/S|indaptusrx.com (INDP) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|calcimedica.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S AFMD (Affimed N.V.)|ALLK - Multiplikator forward rega marang pendapatan|HOOK: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake IGM Biosciences, Inc. IGMS|ITOS: Multiplikator Forward P/S|OCEA - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator forward rega marang pendapatan Third Harmonic Bio Inc (THRD)
